Panel 2:

Research questions regarding fertility, infertility risk and Assisted Reproductive Technology in sickle cell disease

• Define effects of sickle cell disease pathophysiology and treatments on oocyte quality, blastocyst development and miscarriage

• Establish infertility rates and risks in people with sickle cell disease; include all genotypes

• Define gonadoprotection or gonadotoxicity of hydroxyurea, chronic transfusion, and other sickle cell disease therapies in chronically exposed people with attention to dose and duration of treatment

• Establish ideal timing of fertility preserving interventions and study protocols to optimize outcomes and minimize complications

• Identify which sickle cell disease treatments need to be discontinued, and for what time period, before gamete cryopreservation

• Define pregnancy outcomes when cryopreserved gametes are used

• Measure barriers to fertility preservation